Stock 4587 PEPTIDREAM INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus PeptiDream Inc.

Equities

4587

JP3836750004

Delayed Japan Exchange
Other stock markets
 09:33:04 2024-06-12 pm EDT 		5-day change 1st Jan Change
2,159 JPY +0.21% Intraday chart for PeptiDream Inc. +4.23% +45.04%
Jun. 04 National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma CI
May. 14 Peptidream Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 CI

Evolution of the average Target Price on PeptiDream Inc.

Price target over the last 5 years

History of analyst recommendation changes

3794ef90a445b542445.UuJei7PF39JY32lbR5wTeTyNdgDUd9of5vOEAyNlSGk.BasdvuCWt4AOuB5oF61MDAnlG3aQAOwmqoD9QGhTFz0jhhj8i4awvzyUHg~69bc950b9864f4e793c76128cb2680e5

Analyst Recommendations on PeptiDream Inc.

Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold MT
Jefferies Adjusts PeptiDream's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Hold MT
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,300 Yen From 1,600 Yen MT
Jefferies Upgrades PeptiDream to Buy From Hold, Adjusts Price Target to 1,600 Yen From 1,900 Yen MT
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,900 Yen From 2,200 Yen MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2,154 JPY
Average target price
2,850 JPY
Spread / Average Target
+32.28%
High Price Target
4,900 JPY
Spread / Highest target
+127.43%
Low Price Target
1,900 JPY
Spread / Lowest Target
-11.81%

Consensus detail

Consensus revision (last 18 months)

Analysts covering PeptiDream Inc.

Jefferies & Co.

Ratings for PeptiDream Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4587 Stock
  4. Consensus PeptiDream Inc.